Paul Hatala, PhD is a classically trained synthetic chemist with over 15 years’ experience in both biotech and large pharma. Paul specializes in the development and CMC aspects of novel therapeutics, focusing on highly complex entities and conjugates. In his last industrial post, at Baxter Bioscience, Paul concentrated on the development of subcutaneous treatments for hemophilia. Prior to Baxter, Paul led chemistry efforts at Archemix Corp. and worked on therapeutic programs in the rare diseases, oncology, and inflammation. While at Archemix, Paul developed novel methods for the purification of molecules conjugated to half-life extension polymers including PEG.
Paul received his PhD in Chemistry from Syracuse University and his B. Sc. from the University of Denver. Professionally, Paul is active in several scientific organizations including AAPS, in addition to mentoring younger students in the sciences.
Besides CMC leadership, Paul provides a variety of services to clients including: due diligence, subject matter expert (SME), strategic sourcing, project management, and technology transfer and integration to quality/lifecycle management.